Icecure Medical Ltd. (ICCM) has released an update.
IceCure Medical Ltd. has announced the submission of final trial results to the FDA, showing a 96.3% recurrence free rate and 100% patient and physician satisfaction for its ProSense cryoablation technology for early-stage breast cancer treatment. The trial data indicates that IceCure’s minimally invasive procedure, which recently won the Scientific Impact Award, could be a viable alternative to traditional surgery, with potential for rapid adoption due to existing reimbursement codes and favorable healthcare economics.
For further insights into ICCM stock, check out TipRanks’ Stock Analysis page.
